首页 › 三阴性乳腺癌 › 加利福尼亚州 › Los Angeles
Los Angeles CA 三阴性乳腺癌临床试验
27项针对 三阴性乳腺癌的研究正在 Los Angeles及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- University of California - Los Angeles, Los Angeles
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
招募中2 期
- Ellison Institute of Technology (EITM), Los Angeles
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Cedars-Sinai Cancer at Beverly Hills, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
招募中1/2 期
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
招募中1/2 期
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
招募中1/2 期
- Cedars Sinai Medical Center, Los Angeles
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
招募中1/2 期
- Cedars-Sinai Medical Center, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- University of California Los Angeles Medical Center, Los Angeles
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
招募中2 期
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Medical Center Beverly Hills, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
招募中1 期
- University of California LA, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
招募中1 期
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
招募中1 期
- Start Lacn, Los Angeles
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
招募中1 期
- USC / Norris Comprehensive Cancer Center, Los Angeles
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- University of Southern California, Los Angeles
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
招募中2 期
- Cedars-Sinai Medical Center, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
招募中欢迎健康志愿者
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
招募中1/2 期
- Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- University of Southern California, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
招募中1/2 期
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of Southern California, Los Angeles
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
招募中2 期
- Valkyrie Clinical Trials, Los Angeles
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
- Grand Rapids, MI15 项研究
Los Angeles的其他研究
- 非小细胞肺癌87 项研究
- 癌症（所有类型）74 项研究
- 乳腺癌73 项研究
- 前列腺癌61 项研究
- 结直肠癌59 项研究
- 转移性癌症57 项研究
- 卵巢癌50 项研究
- 肺癌45 项研究
- 头颈鳞状细胞癌42 项研究
- 胰腺癌35 项研究
- 子宫内膜癌34 项研究
- 黑色素瘤34 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。